AAPL   322.95 (-0.67%)
MSFT   183.22 (-1.15%)
FB   227.00 (-1.37%)
GOOGL   1,417.73 (-1.50%)
NVDA   351.24 (+0.13%)
BABA   218.74 (+0.06%)
MU   50.83 (+3.90%)
GE   7.46 (+1.36%)
TSLA   877.80 (-0.58%)
AMD   52.49 (-0.46%)
T   31.57 (+0.16%)
ACB   14.17 (-0.91%)
F   6.33 (+1.93%)
GILD   76.23 (+2.46%)
NFLX   417.60 (-1.04%)
BAC   26.19 (+0.92%)
BA   183.96 (+6.24%)
AAPL   322.95 (-0.67%)
MSFT   183.22 (-1.15%)
FB   227.00 (-1.37%)
GOOGL   1,417.73 (-1.50%)
NVDA   351.24 (+0.13%)
BABA   218.74 (+0.06%)
MU   50.83 (+3.90%)
GE   7.46 (+1.36%)
TSLA   877.80 (-0.58%)
AMD   52.49 (-0.46%)
T   31.57 (+0.16%)
ACB   14.17 (-0.91%)
F   6.33 (+1.93%)
GILD   76.23 (+2.46%)
NFLX   417.60 (-1.04%)
BAC   26.19 (+0.92%)
BA   183.96 (+6.24%)
AAPL   322.95 (-0.67%)
MSFT   183.22 (-1.15%)
FB   227.00 (-1.37%)
GOOGL   1,417.73 (-1.50%)
NVDA   351.24 (+0.13%)
BABA   218.74 (+0.06%)
MU   50.83 (+3.90%)
GE   7.46 (+1.36%)
TSLA   877.80 (-0.58%)
AMD   52.49 (-0.46%)
T   31.57 (+0.16%)
ACB   14.17 (-0.91%)
F   6.33 (+1.93%)
GILD   76.23 (+2.46%)
NFLX   417.60 (-1.04%)
BAC   26.19 (+0.92%)
BA   183.96 (+6.24%)
AAPL   322.95 (-0.67%)
MSFT   183.22 (-1.15%)
FB   227.00 (-1.37%)
GOOGL   1,417.73 (-1.50%)
NVDA   351.24 (+0.13%)
BABA   218.74 (+0.06%)
MU   50.83 (+3.90%)
GE   7.46 (+1.36%)
TSLA   877.80 (-0.58%)
AMD   52.49 (-0.46%)
T   31.57 (+0.16%)
ACB   14.17 (-0.91%)
F   6.33 (+1.93%)
GILD   76.23 (+2.46%)
NFLX   417.60 (-1.04%)
BAC   26.19 (+0.92%)
BA   183.96 (+6.24%)
Log in

CVE:LBLLattice Biologics Stock Price, Forecast & News

C$0.05
+0.01 (+11.11 %)
(As of 06/4/2020 01:14 PM ET)
Add
Compare
Today's Range
C$0.05
Now: C$0.05
C$0.05
50-Day Range
C$0.05
MA: C$0.09
C$0.13
52-Week Range
C$0.02
Now: C$0.05
C$0.21
Volume28,400 shs
Average Volume1.96 million shs
Market CapitalizationC$4.67 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic allograft products for use in the field of cellular therapies and tissue engineering with a focus on bone, skin, and cartilage regeneration worldwide. The company offers AmnioBoost, an allograft amniotic fluid visco supplement for the treatment of joint pain associated with osteoarthritis, as well as traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix allografts. Its products are used in a range of applications, including enhancing fusion in spine surgery and breast reconstruction post mastectomy, promotion of bone regeneration in foot and ankle surgery, promotion of skull healing following neurosurgery, enhancing wound repair in burn victims, and subchondral bone defect repair in knee and other joint surgeries, as well as sports medicine indications, such as anterior cruciate ligament repair. The company is headquartered in Belgrade, Montana.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.54 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-604-2356701

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$2.42 million
Book ValueC($0.07) per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$4.67 million
Next Earnings Date9/3/2020 (Estimated)
OptionableNot Optionable

Receive LBL News and Ratings via Email

Sign-up to receive the latest news and ratings for LBL and its competitors with MarketBeat's FREE daily newsletter.

Lattice Biologics (CVE:LBL) Frequently Asked Questions

How has Lattice Biologics' stock been impacted by COVID-19 (Coronavirus)?

Lattice Biologics' stock was trading at C$0.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LBL stock has increased by 66.7% and is now trading at C$0.05. View which stocks have been most impacted by Coronavirus.

When is Lattice Biologics' next earnings date?

Lattice Biologics is scheduled to release its next quarterly earnings announcement on Thursday, September 3rd 2020. View our earnings forecast for Lattice Biologics.

Has Lattice Biologics been receiving favorable news coverage?

Press coverage about LBL stock has been trending somewhat positive recently, InfoTrie reports. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Lattice Biologics earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutLattice Biologics.

Who are some of Lattice Biologics' key competitors?

What other stocks do shareholders of Lattice Biologics own?

Who are Lattice Biologics' key executives?

Lattice Biologics' management team includes the following people:
  • Mr. Guy S. Cook, CEO, Pres & Director (Age 54)

What is Lattice Biologics' stock symbol?

Lattice Biologics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "LBL."

How do I buy shares of Lattice Biologics?

Shares of LBL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Lattice Biologics' stock price today?

One share of LBL stock can currently be purchased for approximately C$0.05.

How big of a company is Lattice Biologics?

Lattice Biologics has a market capitalization of C$4.67 million and generates C$2.42 million in revenue each year.

What is Lattice Biologics' official website?

The official website for Lattice Biologics is www.latticebiologics.com.

How can I contact Lattice Biologics?

Lattice Biologics' mailing address is 16701 N 90th St Ste 101, SCOTTSDALE, AZ 85260-1012, United States. The company can be reached via phone at +1-604-2356701.

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.